How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Sell
35
THNR Quote, Financials, Valuation and Earnings
Last price:
$21.24
Seasonality move
:
--
Day range:
$21.12 - $21.76
52-week range:
$18.56 - $28.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.2K
Avg. volume:
2K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$21.12 | -- | -- | -- | $0.22 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.24 | -- | -- | -- | $0.15 | 0.83% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$8.69 | -- | -- | -- | $0.00 | 0% | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$16.90 | -- | -- | -- | $0.00 | 0% | -- |
|
SYNB
Putnam BioRevolution ETF
|
$27.29 | -- | -- | -- | $0.21 | 0.78% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.837 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.704 | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.823 | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | 1.058 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Global X Aging Population ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is THNR or AGNG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.536%.
-
Which is a Better Dividend Stock THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.15 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns THNR or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is THNR or CNCR More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.057, suggesting its more volatile than the S&P 500 by 5.704%.
-
Which is a Better Dividend Stock THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns THNR or EKG?
First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -
What do Analysts Say About THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 -
Is THNR or EKG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- --
-
Which has Higher Returns THNR or SYNB?
Putnam BioRevolution ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Putnam BioRevolution ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- SYNBPutnam BioRevolution ETF-- -- -- -
What do Analysts Say About THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Putnam BioRevolution ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Putnam BioRevolution ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Putnam BioRevolution ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 SYNBPutnam BioRevolution ETF0 0 0 -
Is THNR or SYNB More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Putnam BioRevolution ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Putnam BioRevolution ETF offers a yield of 0.78% to investors and pays a quarterly dividend of $0.21 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Putnam BioRevolution ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Putnam BioRevolution ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Putnam BioRevolution ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Putnam BioRevolution ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Putnam BioRevolution ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- SYNBPutnam BioRevolution ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Acuity a Good Stock to Buy Now?
Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…
What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
74
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
RGC alert for May 15
Regencell Bioscience Holdings [RGC] is up 19.54% over the past day.
Buy
71
NUTX alert for May 15
Nutex Health [NUTX] is up 1.78% over the past day.
Buy
81
EXEL alert for May 15
Exelixis [EXEL] is up 0.25% over the past day.
